Avicanna Stock Price, News & Analysis

Avicanna Inc. (AVCNF) is a commercial-stage international biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived, cannabinoid-based products and formulations for global medical and pharmaceutical market segments. The company describes itself as having an established scientific platform that spans research and development (R&D), clinical development, and the commercialization of more than thirty proprietary, evidence-based finished products. These activities support four commercial-stage business pillars that together define Avicanna’s business model.

Business Model and Core Pillars

Avicanna’s operations are organized around four primary pillars: a medical cannabis formulary, a medical cannabis care platform, a pharmaceutical products and pipeline segment, and an active pharmaceutical ingredients (API) business. Across these pillars, Avicanna focuses on standardized, evidence-based cannabinoid products and real-world clinical evidence, and works with international partners and subsidiaries to advance cannabinoid-based medicine.

Medical Cannabis Formulary – RHO Phyto™

The RHO Phyto™ medical cannabis formulary is one of Avicanna’s central commercial pillars. According to company disclosures, RHO Phyto offers a diverse range of proprietary products in oral, sublingual, topical, and transdermal formats with varying ratios of cannabinoids. These products are supported by ongoing education for patients and the medical community. RHO Phyto is described as an established medical brand in Canada, available nationwide to patients across several medical channels, and the brand is reported to be expanding into new international markets.

Medical Cannabis Care Platform – MyMedi.ca

MyMedi.ca is a medical cannabis care platform formed with the stated aim of better serving medical cannabis patients’ needs and enhancing the medical cannabis patient journey. Avicanna reports that MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. The platform also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. In addition, MyMedi.ca offers educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.

Pharmaceutical Products and Pipeline – Including Trunerox™

Leveraging its scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based drug candidates that are in various stages of clinical development and, in some cases, commercialization. These pharmaceutical candidates aim to address unmet medical needs in areas such as dermatology, chronic pain, and various neurological disorders.

A key example from this pillar is Trunerox™, described by the company as its first indication-specific pharmaceutical drug. Trunerox is Avicanna’s proprietary oral formulation with 10% cannabidiol (CBD). According to Avicanna, Trunerox received drug registration approval from the Colombian National Institute of Drug and Food Surveillance (INVIMA) as an adjuvant treatment for severe seizures related to Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS), two rare epileptic disorders classified as epileptic encephalopathies. The company notes that Trunerox is manufactured in Colombia under Good Manufacturing Practices (GMP) using CBD produced by its majority-owned subsidiary Santa Marta Golden Hemp SAS (SMGH), and that Trunerox has not been approved as a drug in Canada by Health Canada.

Active Pharmaceutical Ingredients – Aureus Santa Marta™ and SMGH

The fourth pillar is Avicanna’s active pharmaceutical ingredients (API) business, marketed under the Aureus Santa Marta™ brand and operated primarily through its majority-owned subsidiary Santa Marta Golden Hemp SAS (SMGH). Company materials describe SMGH as a commercial-stage business dedicated to providing various forms of high-quality CBD, THC, and CBG to international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of Avicanna’s internal supply chain, serving as a source of reliable input materials for the company’s consumer retail, medical cannabis, and pharmaceutical products globally.

Avicanna has reported that SMGH has exported Aureus-branded products into multiple international markets for research and manufacturing purposes, and that it produces proprietary and premium CBD, CBG, and THC genetics for regions such as Europe and Australia. The company also highlights certifications at SMGH, including Good Agricultural and Collection Practices (GACP) and Organic certifications under the United States Department of Agriculture National Organic Program (USDA) for its hemp cultivars.

Scientific Platform, R&D, and Clinical Development

Avicanna emphasizes an evidence-based approach to cannabinoid-based medicine. The company reports a long-standing focus on research and clinical development initiatives in collaboration with Canadian academic and clinical institutions. Its scientific platform includes R&D programs, pre-clinical work, and clinical development activities that support its proprietary pipeline of drug delivery systems, medical cannabis products, and pharmaceutical candidates.

Examples disclosed by the company include:

• A real-world evidence study conducted in collaboration with University Health Network (UHN) in Canada, enrolling hundreds of patients to evaluate outcomes related to pain, sleep, anxiety, and depression using Avicanna’s medical cannabis products.
• A Phase II randomized controlled trial evaluating arthritic pain utilizing Avicanna’s proprietary cannabinoid formulations.
• A retrospective observational real-world evidence study using RHO Phyto™ Ultra CBD Topical Cream in patients with epidermolysis bullosa (EB), led by clinicians at The Hospital for Sick Children in Toronto, which evaluated wound healing, pain, and itch.
• A real-world evidence study assessing a proprietary transdermal gel containing CBD and CBG in patients with musculoskeletal pain and inflammation, examining patient-reported outcomes across conditions such as arthritis and localized pain.

Drug Delivery Technologies and Intellectual Property

Avicanna also highlights proprietary drug delivery technologies as part of its differentiation. The company has disclosed patents issued by the United States Patent and Trademark Office (USPTO) covering:

• A deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain.
• A self-emulsifying drug delivery system (SEDDS) for oral cannabinoid compositions and methods of treating neuropathic pain.

According to Avicanna, its SEDDS technology is designed for oral cannabinoid delivery, and internal testing has demonstrated shelf-life stability and dispersion performance in biorelevant media that mimic human intestinal fluid. The company positions these technologies as part of its broader mission to explore advanced cannabinoid drug delivery systems for therapeutic benefit.

International Operations and Subsidiaries

Avicanna describes itself as an international biopharmaceutical company with operations and subsidiaries in multiple jurisdictions. In Latin America, Avicanna LATAM SAS, based in Colombia and wholly owned by Avicanna Inc., is focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products. Avicanna LATAM SAS works closely with SMGH for the supply of organic hemp-derived cannabinoids and supports international manufacturing and commercialization efforts.

The company has also reported collaborations and agreements with multinational pharmaceutical companies and wellness brands, including supply and licensing agreements for proprietary topical products and research collaborations to assess Avicanna’s SEDDS technology in combination with partners’ drug delivery formats.

Medical Affairs, Education, and Platforms

Beyond product development and commercialization, Avicanna emphasizes medical affairs and education. The company has described initiatives such as:

• The Avicenna Academy educational initiatives and medical symposiums aimed at healthcare professionals.
• Collaboration with partners like Vectura Fertin Pharma through a joint Scientific and Medical Affairs Committee focused on understanding medical cannabis access and applications in Canada, engaging healthcare professionals, patients, advocacy groups, and insurers.
• The MyMedi.ca medical cannabis care platform, which provides patient support programs and educational resources for clinicians.

These activities are positioned by the company as supporting the responsible integration of medical cannabis into healthcare and improving patient access and support.

Position within Medicinal and Botanical Manufacturing

Within the broader medicinal and botanical manufacturing industry, Avicanna’s disclosures highlight a focus on standardized, evidence-based cannabinoid formulations, vertically integrated supply of cannabinoids through SMGH, and a combination of medical cannabis products, pharmaceutical candidates, and active ingredients. The company’s activities span medical cannabis brands, digital medical platforms, pharmaceutical drug development, and international API supply, all centered on plant-derived cannabinoids.

FAQs about Avicanna Inc. (AVCNF)

• What does Avicanna Inc. do?
  Avicanna Inc. is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of plant-derived, cannabinoid-based products and formulations for global medical and pharmaceutical market segments. Its activities include R&D, clinical development, and commercialization of proprietary cannabinoid-based products.
• What are Avicanna’s main business pillars?
  According to company disclosures, Avicanna’s business is organized into four commercial-stage pillars: the RHO Phyto™ medical cannabis formulary, the MyMedi.ca medical cannabis care platform, a pharmaceutical products and pipeline segment (including Trunerox™), and the Aureus Santa Marta™ active pharmaceutical ingredients business operated through Santa Marta Golden Hemp SAS.
• What is RHO Phyto™?
  RHO Phyto™ is Avicanna’s medical cannabis formulary consisting of proprietary oral, sublingual, topical, and transdermal products with varying cannabinoid ratios. The company states that RHO Phyto is an established medical brand in Canada, available nationwide across several medical channels and expanding into international markets.
• What is MyMedi.ca?
  MyMedi.ca is a medical cannabis care platform formed to better serve medical cannabis patients and enhance the patient journey. Operated by Northern Green Canada Inc., it offers a diverse product portfolio, bilingual pharmacist-led patient support programs, specialty services for groups such as veterans, and collaboration with public and private payers for reimbursement, along with educational resources for healthcare professionals.
• What is Trunerox™ and where is it approved?
  Trunerox™ is Avicanna’s proprietary oral formulation with 10% cannabidiol (CBD). The company reports that it received drug registration approval from Colombia’s health authority INVIMA as an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome. Avicanna also states that Trunerox™ has not been approved as a drug in Canada by Health Canada.
• What is Santa Marta Golden Hemp SAS (SMGH)?
  Santa Marta Golden Hemp SAS is Avicanna’s majority-owned subsidiary that operates the Aureus Santa Marta™ active pharmaceutical ingredients business. SMGH supplies various forms of high-quality CBD, THC, and CBG to international partners for use in food, cosmetics, medical, and pharmaceutical products, and also supplies cannabinoids into Avicanna’s own product lines.
• How does Avicanna approach research and clinical development?
  Avicanna describes having an established scientific platform that includes R&D, pre-clinical work, and clinical development. The company reports collaborations with Canadian academic and clinical institutions, real-world evidence studies in conditions such as musculoskeletal pain and epidermolysis bullosa, and a Phase II randomized controlled trial in arthritic pain using its proprietary formulations.
• What proprietary technologies has Avicanna disclosed?
  The company has reported United States patents covering a deep penetrating topical cannabinoid composition for musculoskeletal inflammation and pain, and a self-emulsifying drug delivery system (SEDDS) for oral cannabinoid compositions and methods of treating neuropathic pain. These technologies are presented as part of Avicanna’s focus on advanced cannabinoid drug delivery.
• In which markets does Avicanna operate?
  Avicanna describes itself as an international company with commercial activities in Canada and Latin America, and with Aureus-branded API exports from SMGH into multiple countries for research and manufacturing. It also reports agreements related to the European region and collaborations in markets such as Colombia and Brazil through partners.
• Is Avicanna focused only on medical cannabis?
  While medical cannabis products and platforms are central to Avicanna’s business, the company also emphasizes pharmaceutical drug candidates such as Trunerox™, as well as active pharmaceutical ingredients used in food, cosmetics, medical, and pharmaceutical products. All of these activities are centered on plant-derived cannabinoids.